Edition:
United Kingdom

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

12.39USD
17 Jan 2019
Change (% chg)

-- (--)
Prev Close
$12.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
79,649
52-wk High
$15.08
52-wk Low
$8.01

Latest Key Developments (Source: Significant Developments)

Chemocentryx Announces Proposed Public Offering Of $75 Mln Of Its Common Stock
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CHEMOCENTRYX INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION OF ITS COMMON STOCK.  Full Article

Chemocentryx Q4 Revenue $56.3 Million Versus $4.9 Million
Friday, 9 Mar 2018 

March 9 (Reuters) - Chemocentryx Inc ::CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 REVENUE $56.3 MILLION VERSUS $4.9 MILLION.Q4 REVENUE VIEW $9.4 MILLION -- THOMSON REUTERS I/B/E/S.QUARTERLY EARNINGS PER SHARE $0.80.  Full Article

Chemocentryx reports Q3 revenue $9.0 million
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Chemocentryx Inc ::Chemocentryx reports third quarter 2017 financial results and recent highlights.Q3 revenue $9.0 million versus I/B/E/S view $9 million.Chemocentryx Inc - ‍expects to utilize cash and cash equivalents in range of $50 million and $55 million in 2017​.Chemocentryx inc - ‍phase iii advocate trial of avacopan remains on track to complete enrollment in mid-2018​.Chemocentryx Inc - ‍plan to launch registration-supporting trial for CCX140 in treatment of focal segmental glomerulosclerosis (FSGS) in Q4 2017​.Chemocentryx Inc - qtrly loss per share $0.13​.  Full Article

BRIEF-Vifor Pharma Increases Equity Investment In ChemoCentryx

* INCREASES EQUITY STAKE IN CHEMOCENTRYX FROM 6.6% TO 21.2% Source text for Eikon: Further company coverage: (Gdynia Newsroom)